The neuroAD Therapy System, from Neuronix Medical, may receive FDA clearance in 2017, according to NeuroNews. The device, intended for use in patients with Alzheimer’s disease, uses focused transcranial magnetic stimulation (TMS) in combination with cognitive training to improve cognitive function.
The neuroAD Therapy System is already available in Europe. See the below video from the corporate website for more information.
This product does not have U.S. FDA regulatory clearance or approval as of January 4, 2017.
[Image courtesy of SBTLNEET/PIXABAY; Video courtesy of NEURONIX MEDICAL]